The First European Interdisciplinary Ewing Sarcoma Research Summit - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Frontiers in Oncology Année : 2012

The First European Interdisciplinary Ewing Sarcoma Research Summit

1 Children’s Cancer Research Institute [Vienna, Austria]
2 Department of Pediatrics [Vienna, Austria]
3 Unidad de Tumores Sólidos Infantiles – Unidad de Investigación Biomédica [Madrid, Spain]
4 Sahlgrenska Academy at University of Gothenburg [Göteborg]
5 Leeds Institute of Molecular Medicine
6 MRI TUM - Klinikum rechts der Isar
7 University Hospital of Salamanca
8 U830 - Unité de génétique et biologie des cancers
9 Universitätsklinikum Münster [Munster, Germany]
10 Goethe-Universität Frankfurt am Main
11 Center for Cancer Rearch [Bethesda, MA, USA]
12 LUMC - Leiden University Medical Center
13 University Children's Hospital [Freiburg, Germany]
14 Department of Pediatrics and Department of Pathology [Ann Arbor, MI, USA]
15 Medical School - Department of Pathology [Ann Arbor, MI, USA]
16 Huntsman Cancer Institute [Salt Lake City]
17 University of Valencia
18 Pediatric Oncology and Hematology [Erlangen, Germany]
19 Ludwig Boltzmann Institute for Cancer Research [Vienna, Austria]
20 Physiopathologie de la résorption osseuse et thérapie des tumeurs osseuses primitives
21 UZH - Universität Zürich [Zürich] = University of Zurich
22 Experimental Oncology Lab - CRS Development of Biomolecular Therapies [Bologna, Italy]
23 Department of Molecular Oncology [British Columbia, Canada]
24 Children's Cancer Research Center [Halle, Germany]
25 Georgetown Lombardi Comprehensive Cancer Center
26 University Children's Hospital of Essen
27 Medizinische Universität Wien = Medical University of Vienna
Pancras C W Hogendoorn
  • Fonction : Auteur
  • PersonId : 907035
Franck Tirode

Résumé

The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.
Fichier principal
Vignette du fichier
2012.FrontiersInOncology.Kovar.pdf (480.71 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-02438693 , version 1 (14-01-2020)

Licence

Paternité - Pas de modifications

Identifiants

Citer

Heinrich Kovar, Javier Alonso, Pierre Aman, Dave N T Aryee, Jozef Ban, et al.. The First European Interdisciplinary Ewing Sarcoma Research Summit. Frontiers in Oncology, 2012, 2, pp.1-10. ⟨10.3389/fonc.2012.00054⟩. ⟨inserm-02438693⟩
74 Consultations
74 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More